JP2022541181A - Ｔｃｒ遺伝子の単離方法 - Google Patents

Ｔｃｒ遺伝子の単離方法 Download PDF

Info

Publication number
JP2022541181A
JP2022541181A JP2022502277A JP2022502277A JP2022541181A JP 2022541181 A JP2022541181 A JP 2022541181A JP 2022502277 A JP2022502277 A JP 2022502277A JP 2022502277 A JP2022502277 A JP 2022502277A JP 2022541181 A JP2022541181 A JP 2022541181A
Authority
JP
Japan
Prior art keywords
cells
tcr
antigen
library
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541181A5 (https=
Inventor
ニコラス マリア シューマッハ アントニウス
リンネマン カーステン
クイルマン トマス
エム． ベンドル ギャビン
エフ．シー． ガディオット ジュール
ダブリュ．ジェイ． ファン ヘイスト イェルン
ゴメス‐エーラント ラクエル
ソフィー シュリッケマ デボラ
Original Assignee
ネオジン セラピューティクス ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネオジン セラピューティクス ビー．ブイ． filed Critical ネオジン セラピューティクス ビー．ブイ．
Publication of JP2022541181A publication Critical patent/JP2022541181A/ja
Publication of JP2022541181A5 publication Critical patent/JP2022541181A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
JP2022502277A 2019-07-15 2020-07-13 Ｔｃｒ遺伝子の単離方法 Pending JP2022541181A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962874125P 2019-07-15 2019-07-15
US62/874,125 2019-07-15
US202062975924P 2020-02-13 2020-02-13
US62/975,924 2020-02-13
US202063024341P 2020-05-13 2020-05-13
US63/024,341 2020-05-13
US202063034157P 2020-06-03 2020-06-03
US63/034,157 2020-06-03
US202063039346P 2020-06-15 2020-06-15
US63/039,346 2020-06-15
PCT/US2020/041824 WO2021011482A1 (en) 2019-07-15 2020-07-13 Method to isolate tcr genes

Publications (2)

Publication Number Publication Date
JP2022541181A true JP2022541181A (ja) 2022-09-22
JP2022541181A5 JP2022541181A5 (https=) 2023-07-18

Family

ID=74211262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502277A Pending JP2022541181A (ja) 2019-07-15 2020-07-13 Ｔｃｒ遺伝子の単離方法

Country Status (12)

Country Link
US (1) US20210040558A1 (https=)
EP (1) EP3999528A4 (https=)
JP (1) JP2022541181A (https=)
KR (1) KR20220075210A (https=)
CN (1) CN114502579A (https=)
AU (1) AU2020315325A1 (https=)
BR (1) BR112022000790A2 (https=)
CA (1) CA3146845A1 (https=)
CL (1) CL2022000085A1 (https=)
MX (1) MX2022000667A (https=)
TW (1) TW202117014A (https=)
WO (1) WO2021011482A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
AU2021320556A1 (en) 2020-08-07 2023-03-09 Neogene Therapeutics B.V. Methods to enrich genetically engineered T cells
TW202242097A (zh) 2021-01-20 2022-11-01 荷蘭商新基因治療公司 經工程化之抗原呈現細胞
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023010436A1 (zh) * 2021-08-05 2023-02-09 卡瑞济(北京)生命科技有限公司 Tcr表达构建体以及其制备方法和用途
WO2023114994A1 (en) * 2021-12-16 2023-06-22 Board Of Regents, The University Of Texas System Personalized ranking and identification of onco-reactive t cell receptors and uses thereof
CN114134221B (zh) * 2022-01-28 2022-04-08 北京肿瘤医院(北京大学肿瘤医院) 一种筛选肿瘤特异tcr的方法
US20250216381A1 (en) * 2022-03-21 2025-07-03 Alaunos Therapeutics, Inc. Methods for Identifying Neoantigen-Reactive T Cell Receptors
CN115341020A (zh) * 2022-08-29 2022-11-15 深圳市美星生物科技有限公司 一种利用lamp技术的急性心梗和心衰外显子测序方法
EP4638712A2 (en) * 2022-12-22 2025-10-29 Bluesphere Bio, Inc. Methods for identifying t cell receptors (tcrs) that bind antigens
WO2024163607A2 (en) * 2023-02-02 2024-08-08 Board Of Regents, The University Of Texas System T-cell receptors targeting egfr and methods of use thereof
EP4550335A1 (en) * 2023-10-31 2025-05-07 Tempus AI, Inc. T cell receptor screening methods
WO2025213105A1 (en) * 2024-04-04 2025-10-09 Biontech Us Inc. Methods for identifying t-cell receptor (tcr) sequences
WO2025240737A1 (en) * 2024-05-16 2025-11-20 Rutgers, The State University Of New Jersey Methods of producing memory t cells in vitro and their use in immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516768A (ja) * 2016-05-25 2019-06-20 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ がんの治療のための免疫チェックポイント阻害剤及び細胞傷害性ｔ細胞

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102480188B1 (ko) * 2012-09-14 2022-12-21 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
EP3234130B1 (en) * 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516768A (ja) * 2016-05-25 2019-06-20 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ がんの治療のための免疫チェックポイント阻害剤及び細胞傷害性ｔ細胞

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J CLIN INVEST., vol. 129, no. 1, JPN6025008563, 2019, pages 324 - 335, ISSN: 0005677348 *
NATURE MEDICINE, vol. 19, no. 11, JPN6024025040, 2013, pages 1534 - 1541, ISSN: 0005677349 *

Also Published As

Publication number Publication date
EP3999528A1 (en) 2022-05-25
EP3999528A4 (en) 2023-10-25
CN114502579A (zh) 2022-05-13
CA3146845A1 (en) 2021-01-21
WO2021011482A1 (en) 2021-01-21
US20210040558A1 (en) 2021-02-11
AU2020315325A1 (en) 2022-02-17
BR112022000790A2 (pt) 2022-04-12
TW202117014A (zh) 2021-05-01
CL2022000085A1 (es) 2022-09-20
MX2022000667A (es) 2022-07-21
KR20220075210A (ko) 2022-06-07

Similar Documents

Publication Publication Date Title
JP2022541181A (ja) Ｔｃｒ遺伝子の単離方法
CN114616467B (zh) 筛选原代人类细胞中的同源t细胞和表位反应性的高通量方法
US20250216381A1 (en) Methods for Identifying Neoantigen-Reactive T Cell Receptors
WO2019183610A1 (en) Tissue resident memory cell profiles, and uses thereof
US20210102168A1 (en) Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
Füchsl et al. High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells
US20220228164A1 (en) Engineered antigen presenting cells
Sharma et al. A synthetic cytotoxic T cell platform for rapidly prototyping TCR function
Khateb et al. Rapid enrichment of progenitor exhausted neoantigen-specific CD8 T cells from peripheral blood
KR20260016919A (ko) 제시된 hpv16-, mart1-, cmv-, ebv-, 또는 인플루엔자-펩티드에 결합하는 t 세포 수용체
US20220308061A1 (en) Method to sequence mrna in single cells in parallel with quantification of intracellular phenotype
Moosmann et al. TCR activation impairs CAR-T cytotoxicity against separate target cells
US20250236915A1 (en) Cd4+ t cell markers, compositions, and methods for cancer
RU2822196C2 (ru) Способы получения клеток, экспрессирующих химерный антигенный рецептор
Hennig et al. A new clustering approach identifies tumor-specific common TCRs with pan-cancer reactivity
WO2024197072A2 (en) Identification of neoantigen-reactive t cell receptors
WO2025122800A9 (en) Identification of neoantigen-reactive t cell receptors
Ramade et al. Systemic neoantigen-specific T cells reveal central determinants of PD-(L) 1 blockade efficacy
HK40104698A (zh) 工程化抗原呈递细胞
Barranco Cádiz, febrero 2024

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902